DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a research report sent to investors on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Price Performance

DRRX opened at $0.76 on Friday. The firm has a 50 day simple moving average of $0.84 and a 200 day simple moving average of $1.17. DURECT has a fifty-two week low of $0.70 and a fifty-two week high of $1.88. The company has a market cap of $23.59 million, a price-to-earnings ratio of -1.25 and a beta of 0.91.

Institutional Trading of DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC grew its position in DURECT Co. (NASDAQ:DRRX) by 4.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the period. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. 28.03% of the stock is currently owned by hedge funds and other institutional investors.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.